Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.

Gold, Ralf; Piani-Meier, Daniela; Kappos, Ludwig; Bar-Or, Amit; Vermersch, Patrick; Giovannoni, Gavin; Fox, Robert J; Arnold, Douglas L; Benedict, Ralph H B; Penner, Iris-Katharina; Rouyrre, Nicolas; Kilaru, Ajay; Karlsson, Göril; Ritter, Shannon; Dahlke, Frank; Hach, Thomas; Cree, Bruce A C (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of neurology, 269(9), pp. 5093-5104. Springer 10.1007/s00415-022-11166-z

Preview

Text Gold2022_Article_SiponimodVsPlaceboInActiveSeco.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (723kB) | Preview

BACKGROUND

Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of siponimod in aSPMS.

METHODS

Post hoc analysis of participants with aSPMS (≥ 1 relapse in 2 years before study and/or ≥ 1 T1 gadolinium-enhancing [Gd +] magnetic resonance imaging [MRI] lesions at baseline) receiving oral siponimod (2 mg/day) or placebo for up to 3 years in EXPAND.

ENDPOINTS

3-month/6-month confirmed disability progression (3mCDP/6mCDP); 3-month confirmed ≥ 20% worsening in Timed 25-Foot Walk (T25FW); 6-month confirmed improvement/worsening in Symbol Digit Modalities Test (SDMT) scores (≥ 4-point change); T2 lesion volume (T2LV) change from baseline; number of T1 Gd + lesions baseline-month 24; number of new/enlarging (N/E) T2 lesions over all visits.

RESULTS

Data from 779 participants with aSPMS were analysed. Siponimod reduced risk of 3mCDP/6mCDP vs placebo (by 31%/37%, respectively; p < 0.01); there was no significant effect on T25FW. Siponimod increased likelihood of 6-month confirmed SDMT improvement vs placebo (by 62%; p = 0.007) and reduced risk of 6-month confirmed SDMT worsening (by 27%; p = 0.060). Siponimod was associated with less increase in T2LV (1316.3 vs 13.3 mm3; p < 0.0001), and fewer T1 Gd + and N/E T2 lesions than placebo (85% and 80% reductions, respectively; p < 0.0001).

CONCLUSIONS

In aSPMS, siponimod reduced risk of disability progression and was associated with benefits on cognition and MRI outcomes vs placebo.

TRIAL REGISTRATION

ClinicalTrials.gov number: NCT01665144.

Interest & Impact

Downloads

58 since deposited on 01 Jun 2022
23 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item